TAMPA, Fla. - eTradeWire -- Juventix Regenerative Medical, a leader in regenerative medicine solutions, proudly announces that its Platelet-Rich Plasma (PRP) technology has been featured in a groundbreaking university-published research study. The study, titled "Platelet-Rich Plasma for Rheumatoid Arthritis: A Case Series", published in the peer-reviewed journal Cureus, underscores the efficacy of Juventix PRP in managing rheumatoid arthritis, showcasing its transformative potential in clinical applications.

The study explores the use of PRP to address inflammation and improve outcomes in rheumatoid arthritis patients, with findings demonstrating measurable benefits attributed to Juventix PRP's advanced process. The research highlights the role of PRP in promoting tissue repair and reducing joint pain, offering a promising non-surgical alternative for patients seeking regenerative therapies.

Scientific Validation Backed by Laboratory Studies
Juventix PRP's inclusion in this research aligns with findings from extensive laboratory evaluations conducted by BioSciences Research Associates (2020) and Biofyl Scientific Research (2023). Key results include:

• 84% platelet recovery, significantly enhancing platelet-derived growth factor (PDGF) concentrations.
• 10x increase in PDGF levels, with treated PRP reaching 10,844 pg/mL compared to 1,536 pg/mL in untreated samples.
• Minimal contamination of red and white blood cells, ensuring safety and reducing inflammatory risks.
• Optimized pH of 7.5, creating an ideal environment for platelet activation and growth factor release.
• Innovative activation methods, including photoactivation and bio-incubation, transforming PRP into PRF for versatile clinical applications.

"The inclusion of Juventix PRP in a peer-reviewed study underscores our commitment to delivering scientifically validated, high-quality regenerative solutions," said Lance Liberti, CEO of Juventix Regenerative Medical. "Our focus on innovation ensures practitioners can trust Juventix PRP for consistent, superior patient outcomes."

More on eTradeWire News

• Go Find Florida is your go-to directory for finding trusted small businesses near you
• MYONIQ LLC Announces Pre-Launch of MYONIQ Nutrition — A New U.S. Performance Supplement Brand
• CU Launches First K-Convenience Store in the United States with Grand Opening in Honolulu, Hawaii
• Arizona's Top Innovators, Business Leaders and Educators Honored at 2025 Governor's Celebration of Innovation
• Bought it today, on sale tomorrow? Not a problem with Bay Gallery's new Price Guarantee

Special Offer for Medical Practitioners
To introduce clinicians to its cutting-edge PRP systems, Juventix is offering a sample PRP kit for only $20. This limited-time opportunity enables practitioners to experience the proven quality of Juventix PRP firsthand.
• Email: hello@juventix.com with the subject line "SAMPLE"
• Visit: https://juventix.com/sample-page/

About Juventix Regenerative Medical, LLC
Founded in 2017 by Lance Liberti, Juventix Regenerative Medical has been a pioneer in non-surgical regenerative solutions, including FDA-cleared PRP kits. The company offers comprehensive products such as centrifuges, LED activators, and bio-incubators to support superior PRP preparation. Juventix also collaborates with prestigious organizations, including the University of South Florida (USF) Health Center for Advanced Medical Learning and Simulation (CAMLS), to host advanced clinical training symposiums.

For more information, visit www.Juventix.com or contact:
📞 (866) 693-4777

More on eTradeWire News

• $142K Administrator vs $38K Families: Westminster Residents Demand Bronson's Resignation
• SAS Intel Launches Fractional Chief Strategic Intelligence Officer Service
• Torch Entertainment Presents The Frozen Zoo
• One Night Only! Wycliffe Gordon Brings A New Orleans Jazz Christmas Celebration to Boca Raton
• UVify to Showcase Global-Scale IFO Platform and Network at IAAPA Expo Orlando — Booth #1966

✉️ Email: hello@juventix.com
Restore, Revive, Regenerate – Juventix Regenerative Medical.